Drugs / KGX105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07702955 | Aug 2026 → Sep 2028 expected | — | Kangabio AUSTRALIA LTD PTY | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KGX105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07702955 ↗ |
| Modality | Other / unclassified | “KGX105 is an investigational EGFR×CD3 TCE prodrug engineered with masked binding domains to reduce on-target, off-tumor toxicity and systemic activation.” NCT07702955 ↗ |
| Target | EGFR | “to target EGFR-positive tumors” NCT07702955 ↗ |